Clinical Report: Comparison of Acute and Late Toxicity in Prostate Cancer Patients

Overview

This study compares acute and early late toxicity in prostate cancer patients treated with moderately hypofractionated radiotherapy (MHRT) versus ultra-hypofractionated radiotherapy (UHRT). Results indicate that UHRT is associated with significantly lower rates of both acute and late toxicity compared to MHRT.

Background

Prostate cancer is the most commonly diagnosed malignancy among men in Colombia, highlighting the need for effective treatment strategies. Radiotherapy plays a crucial role in managing localized prostate cancer, and hypofractionated regimens have emerged as viable options. Understanding the toxicity profiles of these regimens is essential for optimizing patient care and treatment outcomes.

Data Highlights

Key Findings

• Acute toxicity was significantly higher in the MHRT group (25.17%) compared to the UHRT group (11.63%; p=0.013).
• Late toxicity was also more frequent in the MHRT group (37.06%) versus the UHRT group (9.30%; p<0.001).
• Erectile dysfunction was identified as the most common late event in the MHRT group.
• Multivariable analysis indicated that UHRT was associated with lower odds of acute toxicity (aOR 0.44; 95% CI 0.19–0.99; p=0.048).
• The study emphasizes the need for real-world data on toxicity outcomes in Latin America.
• UHRT may enhance treatment efficiency and patient access while maintaining acceptable clinical outcomes.

Clinical Implications

The findings suggest that UHRT may be a preferable option for prostate cancer treatment in terms of reducing both acute and late toxicity. Clinicians should consider these results when discussing treatment options with patients, particularly in middle-income settings.

Conclusion

UHRT demonstrates a favorable safety profile compared to MHRT, indicating its potential as a standard treatment option for prostate cancer. Further research is warranted to confirm these findings in broader populations.

Related Resources & Content

1. Nikitas et al., The Lancet Oncology, 2025 -- Association of Acute and Late Toxicity in Radiotherapy for Prostate Cancer
2. Springer, 2023 -- Toxicity Assessment of Short-term and Long-term Effects in Primary Hypofractionated External Photon Radiation Therapy for Localized Prostate Cancer Patients
3. The ASCO Post, 2015 -- Hypofractionated Radiotherapy Makes Inroads as Primary Treatment of Prostate Cancer
4. The ASCO Post, 2016 -- Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer
5. NCCN, 2026 -- Prostate Cancer Guidelines
6. New England Journal of Medicine, 2024 -- Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
7. The safety and effectiveness of hypofractionated radiotherapy for localized prostate cancer: A systematic review and meta-analysis
8. https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.8f%20NCCN%202.2026%20prostate.pdf
9. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer | New England Journal of Medicine